Quantcast

Latest Miraculins Inc. Stories

2013-10-15 23:04:09

Less than 60 days after acquiring its non-invasive diabetes screening test technology, Canadian biotech firm Miraculins Inc. is planning to expand into China. Winnipeg, Manitoba (PRWEB) October 15, 2013 Less than 60 days after acquiring its non-invasive diabetes screening test technology, Canadian biotech firm Miraculins Inc. is planning to expand into China. Now bound for Beijing, President and CEO Chris Moreau is set to meet with the heads of Cachet Pharmaceutical, an approximately $700...

2013-04-18 23:02:57

The SCOUT system is the first non-invasive diabetes screening system designed to provide a highly sensitive and convenient method for screening for pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. Vancouver, BC (PRWEB) April 18, 2013 Diabetes rates in Canada have doubled over the past decade, with one in every three Canadians projected to have either diabetes or pre-diabetes by 2020. The shocking statistics were published this month by the...

2008-10-15 09:00:47

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has executed a license agreement with Mount Sinai Hospital ("MSH") to acquire the rights to commercialize a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide. A...

2008-10-02 12:06:59

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to update the market on its assay development progress for PSP94 and Vitronectin, the two proteins which comprise the Company's P2V(TM) prostate cancer test. Since the Company's previous update on August 14, 2008, the analytical performance of the PSP94 test has been optimized. The assay is successfully detecting PSP94 from 0.15...

2008-09-24 09:00:49

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent with Mount Sinai Services ("MSS") which would allow MSS to acquire FDA regulated commercial products known as Analyte Specific Reagents ("ASRs") in order to develop in house clinical tests for Miraculins' growing pipeline of biomarkers. Under the agreement, Miraculins will also retain...

2008-09-23 15:00:34

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that the Board of Directors has granted 500,000 options at an exercise price of $0.15 per share to Mr. Christopher Moreau, President and CEO, in accordance with the Company's stock option plan. The options are subject to regulatory approval. About Miraculins Inc. Miraculins is a medical diagnostic development company focused on...

2008-09-18 09:00:11

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has completed the internal review of its gastric cancer program and has confirmed seven blood based protein biomarkers of interest for their potential to separate gastric cancer patients from non-gastric cancer patients. This includes a single marker that performs with a 72% sensitivity at 95% specificity (AUC...

2008-08-14 09:01:14

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that the Company has completed development of a prototype assay for PSP94 (Prostate Secretory Protein) on the Luminex Bio-Plex 200 Protein Array System and plans to manufacture and begin selling PSP94 based test kits for research purposes by the end of 2008. As previously disclosed by Miraculins, PSP94 plays a significant...

2008-08-07 09:01:05

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a term sheet with Mount Sinai Hospital to acquire a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide. Preeclampsia is a devastating disease of pregnancy...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related